EMA Recommends a Change to the Terms of the Marketing Authorisation for Mosunetuzumab By Ogkologos - October 23, 2025 210 0 Facebook Twitter Google+ Pinterest WhatsApp It adopted a new route for administration along with a new pharmaceutical form Source RELATED ARTICLESMORE FROM AUTHOR Pembrolizumab Plus Weekly Paclitaxel, With Or Without Bevacizumab, Improves OS in Patients With Platinum-Resistant Recurrent Ovarian Cancer EMA Recommends Extension of Indications for Serplulimab Adding Relacorilant to Nab-paclitaxel Prolongs OS in Patients with Platinum-Resistant Ovarian Cancer MOST POPULAR Alex Trebek Gets Choked Up Seeing Contestant’s Heartfelt ‘Guess’ As Final... November 14, 2019 Breast Cancer Patient Turns Hospital Robes Into Fashion with ‘Radiation Runway’ February 1, 2022 Toddler Celebrates 11 Months Cancer-Free In Adorable Dance Video With Dad. October 17, 2019 Working Together to Choose a Cancer Treatment Plan: A Caregiver’s Perspective June 16, 2022 Load more HOT NEWS Students Invent Disposable Core Biopsy Needle to Make the Procedure Cheaper We want every scientist to thrive in cancer research Satisfying Snacks “Your Stories” Podcast: Amplifying Patient Voices
